Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
Estado de gracia, la serie dramática de ficción sobre el narcotráfico que aborda por primera vez el polémico tema de la legalización de las drogas en México, se estrena el lunes 4 de junio, en exclusiva a través de Cinelatino, el canal líder de películas en español en Estados Unidos. La serie que cuenta con altos estándares de producción no se ha visto en ningún otro país en el mundo.
Esta producción mexicana es un thriller de suspenso político que presenta un retrato realista sobre el fenómeno del narcotráfico en México, que arroja luz sobre la red de dinero, el poder y la corrupción que alimenta el negocio ilícito de las drogas.
Para más, va a http://www.multivu.com/mnr/56310-cinelatino-estado-de-gracia-mexico-drug-trade-legalization?lang=es
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
http://youtu.be/tHPU2gR_RiI blu cigs National TV ad - I like to smoke but my old cigarettes kept me from smoking where I wanted to. blu electronic cigarettes are different. They have no ash and no offensive odor, so I can enjoy them anywhere. In my car, at work, at my favorite restaurant or even at my friends house. blu has lot's of great USA made flavors and come in four different strengths so I can control my nicotine intake and it cost less than regular cigarettes. blu is the smarter alternative to cigarettes and the best way to take back you're freedom. blu Cigs are available at many fine retailers including, Sheetz, Ingles, Kerr Drug, Harps, Cumberland Farms, H-E-B, Scolari's and Couche-Tard.
http://www.youtube.com/watch?v=9pxuBgfbid0 blu electronic cigarette commercial - blu electronic cigarettes have no ash and no offensive odor, so I can enjoy them anywhere. In my car, at work, at my favorite restaurant or even at my friends house. Four different strengths mean I can control my nicotine intake and it cost less than regular cigarettes. blu is the smarter alternative to cigarettes and the best way to take back you're freedom. blu is available at many fine retailers including, Sheetz, Ingles, Kerr Drug, Harps, Cumberland Farms, H-E-B, Scolari's and Couche-Tard.
Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
According to a recent national survey, 17.1 percent of Americans lack health insurance, and more than nine million of the nation’s uninsured rely on federally qualified health centers (FQHC), non-profit community clinics and free clinics each year for primary care. While these clinics serve the critical health care needs of the uninsured, patients oftentimes cannot afford the medications prescribed by the clinic’s physicians, or navigate a fragmented system that only offers partial solutions. This is a particularly growing problem for America’s working poor.
Today, Medco Foundation and Dispensary of Hope (DOH), a not-for-profit pharmacy-focused social venture for the uninsured, introduced a new, national initiative to substantially improve the supply, delivery and management of critical prescription drugs to thousands of uninsured Americans who are managing a chronic illness.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54424-medco-dispensary-of-hope-prescription-drug-program-clinics-uninsured
http://www.miraclemulti.com MiracleMulti™ The Best Multivitamins on the market for Men, Women, Vegetarians, and Bodybuilding. Once a day Multivitamin for Health, Energy, Focus, Well Being and Anti-aging.***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
Astellas Pharma Europe Ltd. today presented The Economist Innovation 2011 award for Bioscience to one of the world’s most influential biomedical engineers, Dr Robert Langer – the man responsible for founding the field of controlled-release drug delivery and tissue engineering.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/astellaspharma/52158/
